Skip to content Skip to footer
Subscribe Now
VIEWPOINTS_Patrick Mooney_2024
VIEWPOINTS

Intraocular Drug Delivery: Patrick Mooney from SpyGlass Pharma in Conversation with PharmaShots

Shots:  Out of the 5M cataract procedures in the US, around one-fifth are conducted on patients with glaucoma or ocular hypertension. There’s an unmet need for drug delivery for patients who struggle with topical drops  Today, with PharmaShots, CEO of SpyGlass Pharma, Patrick Mooney, sharing insights from the data presented at the ASCRS Annual Meeting  Patrick…
June 10, 2024

Read more

VIEWPOINTS_Donna Carstens_2024
VIEWPOINTS

SEA Management: Donna Carstens from AstraZeneca in a Riveting Conversation with PharmaShots

Shots:  Recently AstraZeneca’s FASENRA (benralizumab) received approval from the US FDA as an add-on maintenance treatment for patients (≥ 6 yrs.) with severe asthma and with an eosinophilic phenotype  Today, at PharmaShots we have with us Donna Carstens, Senior Medical Director Respiratory, Fasenra at AstraZeneca  Donna shares insights from the TATE study an open-label, multinational,…
June 3, 2024

Read more

VIEWPOINTS_Kurt Harrington_2024
VIEWPOINTS

Alternative Treatment: Kurt Harrington from Ventoux Biosciences in a Gripping Conversation with PharmaShots

Shots:  Dupuytren’s disease is a chronic progressive & debilitating fibrosis that impacts hands. There’s an unmet need to treat Dupuytren’s disease, especially when looking for a pharmacological substitute for surgical interventions  Today, at PharmaShots, we had the pleasure to speak with Kurt Harrington, CEO and Founder of Ventoux Biosciences  Kurt shares insights from the preclinical…
May 29, 2024

Read more

VIEWPOINTS_Jason Hannon_2024
VIEWPOINTS

Funds Raised: Jason Hannon from Mainstay Medical in a Stimulating Conversation with PharmaShots

Shots:  Mainstay Medical recently raised $125M in the company’s largest funding round. The financing is intended to accelerate the commercial growth of the company’s ReActiv8, a restorative Neurostimulation therapy in the US, Europe, and Australia  Today, at PharmaShots, we had Jason Hannon, CEO of Mainstay Medical, who talked in great length about the ReActiv8 Restorative Neuromodulation System developed for…
May 27, 2024

Read more

VIEWPOINTS_Jeffrey Lengyel_2024
VIEWPOINTS

Increasing Accessibility: Jeffrey Lengyel from Thermo Fisher Scientific, in an Enlightening Conversation with PharmaShots

Shots:   Advances in Cryo-EM help better understand biological molecules and complexes at atomic resolution. Thermo Fisher Scientific’s recently launched Glacios 2 Cryo-TEM with E-CFEG offers promising potential in reducing the workflow complexities with automation  Today, we have Jeffrey Lengyel Director of Life Sciences, Cryo-EM, at Thermo Fisher Scientific shedding light on Glacios 2 Cryo-TEM with E-CFEG  Jeffrey highlights the significance of the…
May 22, 2024

Read more

VIEWPOINTS_Gavin Magaha_2024
VIEWPOINTS

Drug Discount Solutions: Gavin Magaha from Kalderos, in a Stimulating Conversation with PharmaShots

Shots:  With the implementation of the Inflation Reduction Act (IRA) in 2022, several pricing reforms were introduced, including the new mandated drug pricing and discount elements  Today, we have with us Gavin Magaha, Senior Director, Value Delivery for Kalderos, shedding light on the challenges that come with the IRA act and the impact it puts on…
May 20, 2024

Read more

Disease of the Month – Sjögren’s Syndrome
INSIGHTS+

Disease of the Month – Sjögren’s Syndrome

Shots:  A rare autoimmune condition, Sjögren’s Syndrome is characterized by dry mouth and eye. The condition affects 0.5 to 1% of the global population of which 90% of patients are women  In this reprise of our Disease of the Month report, we bring an illuminating account of Sjögren’s Syndrome with deep dive analysis of epidemiology, market size, disease management, available therapies, patient…
May 16, 2024

Read more

VIEWPOINTS_Andrew Menzies-Gow1_Michael Wechsler2_2024
VIEWPOINTS

EGPA Remission with Fasenra: Michael Wechsler and Andrew Menzies Gow in Conversation with PharmaShots

Shots:  An already established biologic treatment for SEA in the US, EU5 & Japan. Fasenra is now showing exemplary remission for the treatment of Eosinophilic Granulomatosis with Polyangiitis (EGPA)  Today, at PharmaShots, we have a distinguished panel of speakers shedding light on advancements under the P-III MANDARA study and the recent publication of the study…
May 15, 2024

Read more

VIEWPOINTS_Dror Zur_2024
VIEWPOINTS

AI-Aided Colonoscopy Technology: Dror Zur from Magentiq Eye in a Dialogue Exchange with PharmaShots

Shots:  Dror Zur, CEO and Founder of Magentiq Eye in a stimulating conversation with PharmaShots talks about the Lancet Digital Health Study journal that featured MAGENTIQ-COLO™, an AI-aided colonoscopy technology study  MAGENTIQ-COLO™ has already got FDA clearance and a CE mark for polyp detection during colonoscopy. The renewed version includes features like polyp size estimation, polyp characterization, and additional…
May 13, 2024

Read more

Load more